HC Wainwright Has Positive Outlook for CRVS FY2025 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Analysts at HC Wainwright increased their FY2025 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Wednesday, March 26th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings of ($0.43) per share for the year, up from their previous estimate of ($0.44). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2027 earnings at ($0.32) EPS.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06).

Separately, Oppenheimer reissued an “outperform” rating and issued a $15.00 target price (up from $14.00) on shares of Corvus Pharmaceuticals in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.67.

Corvus Pharmaceuticals Stock Up 0.6 %

NASDAQ:CRVS opened at $3.37 on Friday. Corvus Pharmaceuticals has a twelve month low of $1.30 and a twelve month high of $10.00. The firm has a market capitalization of $216.55 million, a price-to-earnings ratio of -3.62 and a beta of 0.91. The stock’s 50 day moving average price is $4.64 and its two-hundred day moving average price is $6.06.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Virtus ETF Advisers LLC acquired a new position in shares of Corvus Pharmaceuticals in the fourth quarter valued at $47,000. PKS Advisory Services LLC acquired a new stake in shares of Corvus Pharmaceuticals during the fourth quarter worth $56,000. Alpine Global Management LLC acquired a new stake in Corvus Pharmaceuticals in the 4th quarter worth about $62,000. ExodusPoint Capital Management LP acquired a new stake in shares of Corvus Pharmaceuticals in the fourth quarter valued at approximately $72,000. Finally, Man Group plc acquired a new stake in Corvus Pharmaceuticals during the fourth quarter worth approximately $73,000. Institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.